Technical aspects and administration methods of 177Lu-DOTATATE for nuclear medicine technologists
AB Davis, MH Pietryka… - Journal of Nuclear …, 2019 - Soc Nuclear Med
At Banner MD Anderson Cancer Center in Arizona, we have gained valuable knowledge of
the different infusion methods for 177Lu-DOTATATE peptide receptor radionuclide therapy …
the different infusion methods for 177Lu-DOTATATE peptide receptor radionuclide therapy …
Guidance on 177Lu-DOTATATE peptide receptor radionuclide therapy from the experience of a single nuclear medicine division
A Abbott, CG Sakellis, E Andersen… - Journal of Nuclear …, 2018 - Soc Nuclear Med
177Lu-DOTATATE is a radiolabeled somatostatin analog that has been approved by the US
Food and Drug Administration (FDA) for the treatment of somatostatin receptor–positive …
Food and Drug Administration (FDA) for the treatment of somatostatin receptor–positive …
177Lu-DOTATATE peptide receptor radionuclide therapy
A Abbott, HA Jacene - J Nucl Med Technol., 2018 - Soc Nuclear Med
Patient education should include a detailed description of the treatment day and
posttreatment care, including possible side effects, instructions about radiation safety to …
posttreatment care, including possible side effects, instructions about radiation safety to …
Nuts and bolts of 177Lu-DOTATATE administration in the nuclear medicine division: guidance from a single institute's experience
A Abbott, CG Sakellis, E Andersen… - Journal of Nuclear …, 2018 - Soc Nuclear Med
[Lutetium-177-DOTA (0), Tyr (3)] octreotate (177 Lu-DOTATATE) is a radiolabeled
somatostatin analog that has been approved by the US Food and Drug Administration for …
somatostatin analog that has been approved by the US Food and Drug Administration for …
In vivo instability of 177Lu-DOTATATE during peptide receptor radionuclide therapy
M Lubberink, H Wilking, A Öst, E Ilan… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Peptide receptor radiotherapy using 177Lu-labeled somatostatin ligand analogs is a well-
established treatment for neuroendocrine tumors, with 177Lu-DOTATATE having acquired …
established treatment for neuroendocrine tumors, with 177Lu-DOTATATE having acquired …
Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use 177Lu-DOTA-TATE: The Intricate Radiochemistry Aspects
A Mathur, V Prashant, N Sakhare… - Cancer Biotherapy & …, 2017 - liebertpub.com
Abstract Introduction: 177Lu-DOTA-TATE is a clinically useful and promising therapeutic
radiopharmaceutical for peptide receptor radionuclide therapy of neuroendocrine tumors …
radiopharmaceutical for peptide receptor radionuclide therapy of neuroendocrine tumors …
Ensuring Safe & Effective Delivery of Lutetium-177 Dotatate Therapy
R Fernandez, S Allen, V Lewington - 2015 - Soc Nuclear Med
479 Objectives This study, based on a large UK single-centre experience, considers a range
of scientific aspects which ensure safe delivery of 177 Lu-dotatate therapy. Methods 156 177 …
of scientific aspects which ensure safe delivery of 177 Lu-dotatate therapy. Methods 156 177 …
Practical aspects of peptide receptor radionuclide therapy with [^ sup 177^ Lu][DOTA^ sup 0^, Tyr^ sup 3^] octreotate
WH Bakker, WAP Breeman… - … quarterly journal of …, 2006 - search.proquest.com
Lutetium-177 is increasingly used in patients for receptor-targeted radionuclide therapy with
peptides such as [DOTA0, Tyr3] octreotate. In our therapy facility, we are performing yearly …
peptides such as [DOTA0, Tyr3] octreotate. In our therapy facility, we are performing yearly …
[HTML][HTML] Validation of an in-house developed therapeutic dosimetric software tool for the treatment of 177Lutetium-DOTATATE peptide receptor radionuclide therapy
Background Computer software for absorbed dose quantification has been used widely in
nuclear medicine. Different software tools have been written to improve the dose …
nuclear medicine. Different software tools have been written to improve the dose …
A rapid and safe infusion protocol for 177Lu peptide receptor radionuclide therapy
SC Ebbers, MW Barentsz, B de Keizer… - Journal of Nuclear …, 2021 - Soc Nuclear Med
Peptide receptor radionuclide therapy (PRRT) with 177Lu-labeled somatostatin analogs in
patients with somatostatin receptor–expressing tumors is often performed using …
patients with somatostatin receptor–expressing tumors is often performed using …